ONC

SEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 3

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,723

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive.

SEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 2

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,440

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

SEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,640

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.22, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (5).

SEC source: 0001104659-17-015904 · a4.xml · nonDerivative · entry 3

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,757

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.68 to $40.07, inclusive.

SEC source: 0001104659-17-015904 · a4.xml · nonDerivative · entry 2

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,061

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

SEC source: 0001104659-17-015904 · a4.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,657

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.07, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (4).

SEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 5

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,478

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.58 to $41.09, inclusive.

SEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 4

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,708

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.50, inclusive.

SEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 3

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,294

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.09, inclusive.

SEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 2

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,794

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.9901, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (6).

SEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,385

F1 · security: Each American Depositary Share represents 13 Ordinary Shares

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

SEC source: 0001104659-17-012149 · a4.xml · nonDerivative · entry 4

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,649

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.49, inclusive.

SEC source: 0001104659-17-012149 · a4.xml · nonDerivative · entry 3

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,093

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.48 to $38.59, inclusive.

SEC source: 0001104659-17-012149 · a4.xml · nonDerivative · entry 2

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,593

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.48 to $38.4784, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (5).

SEC source: 0001104659-17-012149 · a4.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,495

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

SEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 5

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,477

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.20 to $40.87, inclusive.

SEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 4

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,410

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.19 to $40.18, inclusive.

SEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 3

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,836

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.99, inclusive.

SEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 2

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,040

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $40.94, inclusive.

SEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,383

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.58, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (7).

SEC source: 0001209191-16-152165 · doc4.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale transaction reported on this Form 4 was effected as part of an underwritten public offering of Ordinary Shares in the form of American Depositary Shares of the Company in which the Reporting Person was a selling shareholder.

SEC source: 0001179110-16-032122 · edgar.xml · nonDerivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The purchase transaction reported on this Form 4 was effected as part of an underwritten public offering of Ordinary Shares in the form of American Depositary Shares of the Company.

SEC source: 0001638599-16-001591 · doc4_4343.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,317,977

F3 · ownership.nature: After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F5 · ownership.nature: On November 18, 2016, 667 and Life Sciences purchased 165,824 and 1,594,671 American Depositary Shares of the Issuer, respectively, each representing 13 Ordinary Shares (the "ADS") for $32.00 per ADS, pursuant to an underwritten public offering.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-16-001591 · doc4_4343.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 355,198

F2 · ownership.nature: After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: On November 18, 2016, 667 and Life Sciences purchased 165,824 and 1,594,671 American Depositary Shares of the Issuer, respectively, each representing 13 Ordinary Shares (the "ADS") for $32.00 per ADS, pursuant to an underwritten public offering.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001179110-16-031848 · edgar.xml · derivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,047,500

Underlying: Ordinary Shares · 2,047,500 shares

Expires 2026-11-15

F2 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares subject to this option are subject to accelerated vesting upon a change in control or certain termination events.

F2 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

SEC source: 0001179110-16-031842 · edgar.xml · derivative · entry 1

Liang Howard · CIK 0001663427 · CFO & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,752,500

Underlying: Ordinary shares · 1,752,500 shares

Expires 2026-11-15

F2 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event.

F2 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

SEC source: 0001179110-16-031840 · edgar.xml · derivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,613,430

Underlying: Ordinary Shares · 1,613,430 shares

Expires 2026-11-15

F2 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event.

F2 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

F2 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares.

SEC source: 0001179110-16-030099 · edgar.xml · nonDerivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.01 to $31.33, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-030099 · edgar.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,300

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $30.00 to $31.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-030068 · edgar.xml · nonDerivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 41,463

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $29.50 to $30.41, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-030068 · edgar.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 67,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $29.50 to $30.32, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-030037 · edgar.xml · nonDerivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 88,612

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $30.50 to $31.44, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-030037 · edgar.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 100,045

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.43, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 4

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 125,055

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.50, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 3

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 141,373

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.13, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 149,616

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $32.01 to $32.30, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 151,516

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $32.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range.

F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company.

SEC source: 0001179110-16-029407 · edgar.xml · derivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400,000

Underlying: Ordinary Shares · 1,400,000 shares

Expires 2016-09-02

F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001179110-16-029407 · edgar.xml · nonDerivative · entry 1

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 7

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,881,997

F9 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5.

SEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 6

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,882,000

F8 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5.

SEC source: 0001635698-16-000062 · form4.xml · derivative · entry 5

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Via wholly owned subsidiary, MSDRG

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,128,205 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

F1 · derivative.exercise_price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F3 · derivative.exercise_date: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date.

F3 · derivative.expiration_date: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date.

F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0001635698-16-000062 · form4.xml · derivative · entry 4

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Via wholly owned subsidiary, MSDRG

Disclosed balance after: 0

Underlying: Ordinary Shares · 18,518,519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F1 · derivative.exercise_date: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F1 · derivative.expiration_date: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 3

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Via wholly owned subsidiary, MSDRG

Disclosed balance after: 7,942,314

F4 · kind: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85.

F4 · price: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85.

F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 2

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Via wholly owned subsidiary, MSDRG

Disclosed balance after: 5,128,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date.

F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 1

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Via wholly owned subsidiary, MSDRG

Disclosed balance after: 18,518,519

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.

F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.